Publication
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (27)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 27
- cancerChronic Myeloid Leukemia, BCR-ABL1 Positivecivic_curation1.00
- drugDasatinibcivic_curation1.00
- geneABL1civic_curation1.00
- variantABL1 D276Gcivic_curation1.00
- variantABL1 E255Kcivic_curation1.00
- variantABL1 E255Vcivic_curation1.00
- variantABL1 E279Kcivic_curation1.00
- variantABL1 E355Gcivic_curation1.00
- variantABL1 E459Kcivic_curation1.00
- variantABL1 F317Lcivic_curation1.00
- variantABL1 F359Ccivic_curation1.00
- variantABL1 F359Icivic_curation1.00
- variantABL1 F359Vcivic_curation1.00
- variantABL1 F486Scivic_curation1.00
- variantABL1 Fusioncivic_curation1.00
- variantABL1 G250Ecivic_curation1.00
- variantABL1 H396Rcivic_curation1.00
- variantABL1 L248Vcivic_curation1.00
- variantABL1 L384Mcivic_curation1.00
- variantABL1 L387Mcivic_curation1.00
- variantABL1 M244Vcivic_curation1.00
- variantABL1 M351Tcivic_curation1.00
- variantABL1 Q252Hcivic_curation1.00
- variantABL1 T315Icivic_curation1.00
- variantABL1 TKD Mutationcivic_curation1.00
- variantABL1 V299Lcivic_curation1.00
- variantABL1 Y253Hcivic_curation1.00
Curated evidence
Evidence citing this paper (62)
50 items per page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 19779040
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ABL1 L364I + ABL1 Fusion1 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID4485In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 L384M + ABL1 Fusion1 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Resistance | 1 | accepted | EID4527This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 L387M + ABL1 Fusion1 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Does Not Support Resistance | 3 | accepted | EID4406This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 M244V + ABL1 Fusion1 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | B | Does Not Support Resistance | 3 | accepted | EID4302This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 M351T + ABL1 Fusion1 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | B | Does Not Support Resistance | 4 | accepted | EID4396This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 Q252H + ABL1 Fusion1 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Does Not Support Resistance | 3 | accepted | EID4327This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 S417Y + ABL1 Fusion1 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID4713In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 T315I + ABL1 Fusion1 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | B | Supports Resistance | 3 | accepted | EID4365This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 TKD Mutation + ABL1 Fusion1 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | A | Supports Sensitivity Response | 5 | submitted | EID11342In this analysis of three clinical trials (CA180-013 (START-C), a phase 2 trial of dasatinib 70 mg twice daily in 387 patients with resistance (n = 288) or intolerance (n = 99) to imatinib; CA180- 017… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 V299L + ABL1 Fusion1 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Resistance | 1 | accepted | EID4540This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 Y253F + ABL1 Fusion1 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID4343In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 Y253H + ABL1 Fusion1 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | B | Does Not Support Resistance | 3 | accepted | EID4335This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |